Skip to main content
MedPathMedPath Home
Clinical Trials/NCT00652223
NCT00652223
Completed
Phase 1

Safety, Immunogenicity and Clinical Efficacy of an Allergen Vaccine (AllQbG10) in Subjects With Allergic Rhino-Conjunctivitis and Asthma Due to House Dust Mite Allergy

Cytos Biotechnology AG1 site in 1 country21 target enrollmentMarch 2005
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsPerennial Allergic RhinoconjunctivitisAllergic Asthma

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Perennial Allergic Rhinoconjunctivitis
Sponsor
Cytos Biotechnology AG
Enrollment
21
Locations
1
Status
Completed
Last Updated
18 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSitesSimilar Trials

Overview

Brief Summary

The purpose of the study is to test the safety, tolerability, immunogenicity and clinical efficacy of the combination treatment AllQbG10 in patients with rhino-conjunctivitis and asthma due to house dust mite allergy in a single-center, open-label setting.

Registry
clinicaltrials.gov
Start Date
March 2005
End Date
November 2005
Last Updated
18 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • •Mild to moderate perennial allergic rhinoconjunctivitis due to sensitization against house dust mites
  • •Mild asthma
  • •Females only if non-reproductive or agree to practice an effective and accepted method of contraception

Exclusion Criteria

  • •Relevant cardiovascular, renal, pulmonary or endocrine disease
  • •History of autoimmune disease
  • •Severe allergies
  • •History of active infectious disease
  • •Current diagnosis or history of malignancy
  • •Relevant neurological or psychiatric disorder
  • •Pregnancy or lactation
  • •History of alcohol abuse or other recreational drugs
  • •Use of an investigational drug within three month before enrolment
  • •Blood donation within 30 days before enrolment

Outcomes

Primary Outcomes

Not specified

Study Sites (1)

Loading locations...

Similar Trials

Recruiting
Early Phase 1
Study of KRAS Neoantigen mRNA Vaccine (ABO2102) in Patients With KRAS -Mutated Solid Tumors
NCT06577532Ruijin Hospital56
Completed
Phase 3
Safety, Immunogenicity, and Relative Efficacy of H1N1 Vaccines in Adults Aged 18 Years and OlderInfluenza
NCT00979602GlaxoSmithKline4,048
Completed
Phase 2
Safety of gpASIT+TM Subcutaneously Administered to Hay Fever Patients With or Without Immunoregulating AdjuvantHay Fever
NCT01506375BioTech Tools S.A.24
Completed
Phase 1
Safety of and Immune Response to a DNA HIV Vaccine Followed by an Adenoviral Vaccine Boost Given Three Different Ways to HIV Uninfected AdultsHIV Infections
NCT00384787National Institute of Allergy and Infectious Diseases (NIAID)90
Completed
Phase 1
A Study of Single and Multiple Dose Administration of LP-001 in Healthy SubjectsMyelodysplastic Syndrome (MDS)
NCT06294275Longbio Pharma68